Skip to main content
Equibles
MET logo

MET · Metlife Inc

Track MET — free

Use MET with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MET.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$95.92 -0.72 (-0.75%)
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$61.67B
Shares
635.48M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$96.64 Open$97.44 Day$96.54–97.84 52W close$67.70–99.95 Avg vol 30d2.9M Short int11.9M · 1.9% float · 4.0d Short vol44% Last earningsAug 6, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Nov 5, 2026 Est · unconfirmed · in 6 wks
Latest filing: 10-Q
filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$79.40B
Trailing 12 months
Net income (TTM)
$3.63B
Trailing 12 months
Revenue growth YoY
+10.5%
Year over year
Operating margin
8.3%
Trailing 12 months
P / E (TTM)
18.5
Trailing earnings · reciprocal yield 5.4%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-4.2%
Year over year · fewer shares
Price change (1Y)
+22.1%
Trailing year
Short interest
1.9%
Latest settlement · 4.0 days to cover
View all 115 metrics

Equibles Research

our published analysis of this company

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very Low
Market backdrop VIX 14.9 · calm Equity put/call 0.53
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +16%
above
Price vs 50-day avg +1%
above
RSI (14) 51
neutral
MACD trend Negative
52-week position 90%
near high
Momentum
relative strength
Very Strong
1-month return +2%
trailing
6-month return +42%
trailing
YTD return +22%
this year
Relative strength +19%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $96 › 200d $83 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +175 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.87% of float · ▲ +4.8% MoM · 4.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
1,458 holders — near 3-yr high, broad support
Squeeze score 58
elevated · 0–100
Fundamentals
Strong
Revenue growth +9%
Y/Y
EPS growth −21%
Y/Y
Valuation P/E 18.6
rich
Buyback $3.0B
authorized
Balance sheet $7.2B
net cash
Quant / Vol
risk profile
Very Low
Volatility 24%
annualized · 1-yr
Max drawdown −18%
past year
ATR 1.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 5, 2026
full-year 2026
Variable investment income (VII) Initiated $1.6B
Adjusted return on equity Non-GAAP Initiated 15% – 17%
fiscal year ended March 31, 2026
Japan Economic Solvency Ratio (ESR) Initiated 170% – 190%
Prior guidance period ended · from the 8-K filed Jul 31, 2024
Variable investment income (VII) · full year 2024 at least $1.5B

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+16% Bullish
Price vs 50-day avg
+1% Bullish
RSI (14)
51 Neutral
MACD trend
Negative Bearish
52-week position
90% Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $96 › 200d $83 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +175 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.87% of float · ▲ +4.8% MoM · 4.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
1,458 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $68 Now $97 · 90% Range high $100
vs 200-day avg +16% vs 50-day avg +1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Insurance - Life — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MET
Metlife Inc
this stock
$61.67B +22.4% +8.6% 18.6 1.9%
CILJF
China Life Insurance Co Ltd
 $106.56B +9.3% — — 0.0%
MFC
Manulife Financial Corp
 $73.53B +22.9% — — 0.9%
GWLIF
Great-West Lifeco Inc.
 $59.77B +36.0% — — 0.8%
AFL
Aflac Inc
 $58.32B +4.5% -9.3% 12.6 2.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
1,458
% held
77.4%
Net QoQ
+1.1M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
875
View
Short & Settlement
Short Interest Rising
Shares short
11.9M
Days to cover
4.0d
Change
+543.6K sh
View
Short Volume
Short vol %
44%
As of
Sep 22, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$97
As of
Aug 31, 2026
View
Off-Exchange
Off-exchange %
38.3%
Week of
Aug 17, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Alan Armstrong
Amount
$1.0K–$15.0K
Traded
Mar 27, 2026
View
Financials
Financials
Revenue (FY)
$77.1B
Net income (FY)
$3.4B
EPS diluted
$4.71
View
Buybacks
Authorized
$3.0B
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 17, 2026
This year
17
View
Proposed Sales
Value
$1.7M
Shares
21.3K
Filed
Jun 1, 2026
View
Earnings & Events
Earnings Calls
Last call
Aug 6, 2026
View
Investor Relations
Latest news
MetLife to Announce Second Quarte…
Published
Jul 9, 2026
View

Performance

5D 20D 120D MTD YTD
MET -1.1% +2.4% +41.6% +1.5% +22.4%
SPY +1.7% +1.0% +22.4% +0.8% +13.4%
vs SPY -2.8% +1.4% +19.2% +0.7% +9.0%

Capital returns

Buyback program · as of Aug 5, 2026
Authorized
$3.00B
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1099219 CUSIP 59156R108 13F (30d) 27 filings 23 filers Visit website Investor relations